CIPLA LTD vs MONO PHARMACARE LIMITED
A side-by-side comparison of CIPLA LTD (CIPLA) and MONO PHARMACARE LIMITED (MONOPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, CIPLA LTD leads CIPLA vs MONOPHARMA on 11 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability40
- Growth11
- Size & financial health40
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
CIPLA takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
EvenThree-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
CIPLA takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
- + ["Stock is trading at 0.50 times its book value"]
- − ["Though the company is reporting repeated profits, it is not paying out dividend", "Company has low interest coverage ratio.", "Company has a low return on equity of 7.18% over last 3 years.", "Company might be capitalizing the interest cost", "Company has high debtors of 165 days."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.